Ascorbic acid salt of sunitinib

1. A crystalline Form I of an ascorbic acid salt of sunitinib characterized by an XRPD pattern substantially as depicted in FIG. 1 .

2. The crystalline Form I of an ascorbic acid salt of sunitinib according to claim 1 , characterized by XRPD peaks at interplanar spacing (d) values at about 8.00, 7.84, 6.08, 3.99, 3.79, and 3.33 (Å).

3. The crystalline Form I of an ascorbic acid salt of sunitinib according to claim 2 , further characterized by XRPD peaks at interplanar spacing (d) values at about 15.97, 11.47, 10.53, 9.65, 8.00, 7.84, 6.70, 6.08, 5.68, 5.31, 4.80, 4.52, 3.99, 3.79, 3.33, 2.82, and 2.42 (Å).

4. The crystalline Form I of an ascorbic acid salt of sunitinib according to claim 1 , characterized by a DSC thermogram substantially as depicted in FIG. 2 .

5. The crystalline Form I of an ascorbic acid salt of sunitinib according to claim 1 , characterized by DSC endothermic peaks at about 90.78° C., 145.14° C., 155.95° C., 196.09° C., and about 211.33° C.

6. A process for the preparation of the crystalline Form I of claim 1 comprising:

a) treating sunitinib with an ascorbic acid; and

b) isolating the crystalline Form I from the reaction mixture of step a).

7. The process according to claim 6 , wherein the ascorbic acid used for the preparation of the salt of sunitinib is L-ascorbic acid, D-ascorbic acid, or mixtures thereof.

8. The process according to claim 7 , wherein the ascorbic acid used for the preparation of the salt of sunitinib is L-ascorbic acid.

9. The process according to claim 6 , wherein the treatment of sunitinib with an ascorbic acid is carried out in the presence of an organic solvent selected from the group consisting of water, ethers, alcohols, ketones, hydrocarbons, esters, halogenated hydrocarbons, and mixtures thereof.

10. The process according to claim 9 , wherein the ether solvents are selected from the group consisting of methyl tertiary butyl ether, tetrahydrofuran, or diethyl ether.

11. The process according to claim 9 , wherein the alcohol solvents are selected from the group consisting of methanol, ethanol, or n-butanol.

12. The process according to claim 9 , wherein the ketone solvents are selected from the group consisting of acetone or methyl ethyl ketone.

13. The process according to claim 9 , wherein the hydrocarbon solvents are selected from the group consisting of pentane, hexane, or heptane.

14. The process according to claim 9 , wherein the ester solvents are selected from the group consisting of ethyl acetate, butyl acetate, or isopropyl acetate.

15. The process according to claim 9 , wherein the halogenated hydrocarbon is dichloromethane.

16. The process according to claim 9 , wherein the organic solvent is methanol or methyl tertiary butyl ether.

17. A pharmaceutical composition comprising the crystalline Form I of claim 1 and a pharmaceutically acceptable carrier.

18. A method of treating or preventing a protein kinase related disorder, comprising administering to a patient in need thereof a therapeutically effective amount of the crystalline Form I of claim 1 .